| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MENLO PARK, Calif.—It's been a bit of an up-and-down for Pacific Biosciences (PacBio) lately. On Sept. 1, the company was named as a defendant in a complaint filed by Helicos Biosciences Corp. claiming infringement of Helicos patents in the making, using, and selling PacBio's SMRT technology for single molecule sequencing of DNA and teaching customers how to use the SMRT technology and PacBio RS sequencing platform.

Then good news on Oct. 26 as PacBio announced an initial public offering of 12.5 million shares of its common stock at $16 per share to raise $200 million—and a couple days later, the Wall Street Journal reported that the company was closing 44 cents higher—a 2.8 percent jump--at $16.44, in by the close of Nasdaq trading.

Now, some bad news again as GenomeWeb Daily News reported Nov. 4 that Affymetrix Inc. has filed a lawsuit against Pacific Biosciences, alleging misconduct in its hiring of former Affymetrix employees.

In a case filed in California's Santa Clara County Superior Court, Affymetrix alleged, among other things, that "PacBio engaged in tortious misconduct by conspiring with current and former Affymetrix employees to solicit and hire current Affymetrix employees for the PacBio workforce," according to a spokesperson for Santa Clara, Calif.-based Affymetrix, who spoke with GenomeWeb Daily News. Reportedly, some former employees of Affymetrix are also named as defendants in the case.

The spokesperson gave no further comment on the litigation and PacBio also declined comment, reportedly not having yet been served any papers related to the case.


 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue